Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-15
2007-05-15
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S269000, C544S122000, C544S123000, C544S319000
Reexamination Certificate
active
10799507
ABSTRACT:
The present invention relates to compounds of formula I that are useful as GSK-3 inhibitors. The invention also relates to methods of using compounds of formula I or pharmaceutical compositions comprising compounds of formula I to inhibit GSK-3 activity. The invention further provides methods of utilizing these compounds and pharmaceutical compositions in the treatment and prevention of various GSK-3-mediated disorders, such as diabetes and Alzheimer's disease.
REFERENCES:
patent: 1 074 549 (2003-11-01), None
patent: WO 01/70728 (2001-09-01), None
patent: WO 02/096905 (2002-12-01), None
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Casanova et al., PubMed Abstract (Rev Neurol 28(9):909-15), May 1999.
Hardt et al., Glycogen Synthase Kinase-3beta., Circulation Research, 90:1055-1063, May 2002.
Mittelbach et al., CAPLUS Abstract 92:146395, 1980.
Abdel-Megid et al., CAPLUS Abstract 139:36510, 2003.
Abdel-Megid, CAPLUS Abstract 133:30702, 2000.
Kobayashi et al., CAPLUS Abstract 88:31980, 1978.
Gary W. Cline et al, “Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor on Insulin-Stimulated Glucose Metabolism in Zucker Diabetic Fatty(fa/fa) Rats”, Diabetes, 51: 2903-2910 (2002).
Erik J. Henriksen et al, “Modulation of Muscle Insulin Resistance by Selective Inhibition of GSK-3 in Zucker Diabetic Fatty Rats”, American Journal of Physiology Endocrinology and Metabolism, 284: E892-E900 (2003).
Che Jennifer G.
Dixon Lisa A.
Rao Deepak
Vertex Pharmaceuticals Incorporated
LandOfFree
4-Substituted-5-cyano-1H-pyrimidin-6-(thi)ones as GSK-3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-Substituted-5-cyano-1H-pyrimidin-6-(thi)ones as GSK-3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-Substituted-5-cyano-1H-pyrimidin-6-(thi)ones as GSK-3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3784684